INTRODUCTION
============

The incidence of primary penile cancer is very low in Western countries (\<1.00 per 100,000 males) and is decreasing \[[@B1]\]. Primary penile cancer is also rare in Korea, with few cases reported. In Korea, penile cancer was diagnosed in 69 patients in 2011, corresponding to 0.06% of all malignancies in that year \[[@B2]\]. The incidence of penile cancer is related to general hygiene, cultural differences, and the prevalence of human papillomavirus (HPV) infection. HPV prevalence may account for the considerable geographic variation in the incidence of penile cancer \[[@B3]\].

Most penile cancer is squamous cell carcinoma and begins on the foreskin or the tip of the penis. Squamous cell carcinoma grows slowly; therefore, primary penile cancer can usually be cured if it is detected at an early stage. However, patients with carcinoma of the penis tend to delay seeking medical attention, with 65% delaying medical attention for more than 6 months after onset. This delay has been attributed to embarrassment, guilt, fear, ignorance, and personal neglect \[[@B4]\].

To assess the clinicopathologic characteristics of penile cancer, we present the first multicenter study of Korean patients, describing our experience with primary penile cancer patients treated at 6 tertiary academic hospitals.

MATERIALS AND METHODS
=====================

We retrospectively reviewed the medical records of all cases of primary penile cancer treated at our institutions. Between January 2005 and July 2015, 71 such patients were identified at 6 institutions: Pusan National University Yangsan Hospital, Gyeongsang National University Hospital, Dong-A University Hospital, Kosin University Gospel Hospital, Inje University Haeundae Paik Hospital, and Pusan National University Hospital. The study protocol was exempt from the Institutional Review Board of Pusan National University Yangsan Hospital (IRB No. 05-2014-100).

The diagnosis was made according to clinical history, physical examination, and biopsy results. The primary treatment for penile lesions was partial or total penectomy, chemotherapy, and radiation therapy. Patients with clinically or radiologically evident inguinal or pelvic nodal involvement also underwent ipsilateral ilioinguinal lymphadenectomy with contralateral superficial inguinal or ilioinguinal dissection based on their clinical circumstances. Lymph node packets were dissected following standardized protocols. Tumor staging was standardized according to the American Joint Committee on Cancer (AJCC) system \[[@B5]\]. Tumors were graded as well, moderately, or poorly differentiated; carcinoma *in situ* was grouped with well-differentiated tumors for analysis.

Patients\' records were reviewed to identify the mode of therapy, pathology reports, and cancer-specific survival (CSS) rate.

Categorical variables were compared using the chi-square test and the Fisher exact test. CSS rates were calculated by the Kaplan-Meier method as time from the date of surgery or biopsy to the date of progression or cancer-specific death; patients who were alive at the end of the study were censored at the last follow-up. Multivariate analysis was performed using a Cox proportional hazards model that included the AJCC disease stage and tumor grade as covariates. The p-values \<0.05 were considered to indicate statistical significance. Statistical analyses were performed using PASW Statistics ver. 18.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

A total of 71 cases met the inclusion criteria. Seventeen patients were excluded from the final analysis because of incomplete records or loss to follow-up. The clinicopathologic and outcome information of 52 male patients was available. The mean age at diagnosis was 64.3 years (range, 16\~97 years). The mean follow-up was 61.4 months (range, 7\~120 months). All patients were uncircumcised, with the exception of 2 cases of penile paraffinoma involving chronic inflammation of the penis. At presentation, 17 patients were node-positive, and 4 had metastatic disease. Initial treatment included partial penectomy (n=34, 65.4%), total penectomy (n=12, 23.1%) and chemotherapy or radiotherapy (n=6, 11.5%) ([Table 1](#T1){ref-type="table"}). Inguinal lymph node dissection was performed in 20 patients (43.5%). The most frequent pathologic diagnosis was squamous cell carcinoma (n=50, 96.2%) but leiomyosarcoma was observed in 2 cases (3.8%). The final specimens were staged as ≤pT1 (n=23, 44.2%), pT2 (n=13, 25.0%), pT3 (n=14, 26.9%), or pT4 (n=2, 3.8%). Overall, 35 patients (67.3%) had node-negative disease, 17 patients (32.7%) had node-positive disease, and 4 patients (7.7%) had metastatic disease. The penile cancer specimens showed largely mild to moderate differentiation (n=43, 82.7%) ([Table 1](#T1){ref-type="table"}). Kaplan-Meier survival analysis showed a 5-year CSS rate of 84.0% ([Fig. 1](#F1){ref-type="fig"}).

The associations of clinicopathologic variables with survival are shown in [Table 2](#T2){ref-type="table"}. Age, mode of therapy, and operative methods were not significantly associated with survival duration. However, the AJCC stage (p=0.000) and pathologic grade (p=0.019) were associated with survival ([Fig. 2](#F2){ref-type="fig"}). In a multivariate Cox proportional hazards analysis, AJCC stage (p=0.001) and pathologic grade (p=0.038) were independent predictive factors for survival ([Table 2](#T2){ref-type="table"}).

DISCUSSION
==========

Penile cancer is a rare solid cancer with an incidence of \<1.0 per 100,000 males in Europe and the USA \[[@B1]\], but other parts of the world have a much higher incidence (1%\~2% of male malignant disease) \[[@B6]\]. Countries and cultures practicing routine neonatal or youth circumcision have a lower incidence of penile cancer. The incidence of penile cancer is lowest in Israel (neonatal circumcision) and South Korea (youth circumcision) at 0.1 per 100,000 males; the majority of men in these countries are circumcised \[[@B2][@B7]\]. Penile cancer becomes more common with age and its incidence peaks during the sixth decade of life \[[@B8]\]. Most penile cancer patients in South Korea are elderly males in their 70s, 60s, and 50s, whose risk is elevated by 38.2%, 22.1%, and 20.6%, respectively \[[@B2]\].

The etiologic and epidemiologic risk factors for penile cancer are HPV infection, phimosis, smoking, and poor hygiene. HPV DNA is found in 70% to 100% of intraepithelial neoplasias, and up to 42% of penile cancer patients are HPV-positive \[[@B3]\]. The presence of phimosis is strongly associated with invasive penile cancer, likely due to smegma, which is associated with chronic infection and inflammation of the glans and prepuce \[[@B8]\]. Tobacco use, with a 4.5-fold increased risk (95% confidence interval, 2.0\~10.1); chronic penile inflammation; and lichen sclerosus are also associated with an increased risk of penile cancer \[[@B9][@B10]\]. In contrast, circumcision helps to prevent retention of smegma, phimosis, and lichen sclerosus, and reduces the risk of HPV infection \[[@B11]\]. All patents in our study were uncircumcised, with the exception of 2 patients with penile paraffinoma.

Squamous cell carcinoma accounts for \>95% of cases of malignant diseases of the penis. Penile squamous cell carcinoma has been described as a locoregional disease with a low incidence of distant metastasis. Moreover, most penile tumors are low-grade. Previous studies have suggested lymph node metastasis to be the main prognostic factor in this disease \[[@B12][@B13][@B14]\]. In this study, 50 patients (96.2%) had squamous cell carcinoma and 43 patients (82.7%) had well to moderately differentiated tumors.

Lymphovascular or perineural invasion and histologic grade are strongly predictive of a poor prognosis and cancer-specific mortality \[[@B12][@B13][@B14]\]. Any tumor with high-grade features is prone to having a poorer prognosis and a higher likelihood of metastasis \[[@B15]\]. We conducted a survival analysis using the Kaplan-Meier methodology and carried out univariate and multivariate analyses to identify prognostic factors. In the univariate analysis, AJCC stage and pathologic grade were significantly associated with a reduced survival rate. In a multivariate analysis using Cox regression, AJCC stage and pathologic grade were also associated with a reduced survival rate.

The presence of inguinal lymph node involvement was the most important prognostic factor in this study. Ravi \[[@B16]\] demonstrated a 5-year survival benefit (95% *vs*. 76%) in patients with no lymph node involvement (N0) versus inguinal lymph node involvement (N1 and N2). Our study showed a better prognosis in patients with AJCC stage less than IIIA than in those with stage IIIB and IV disease ([Fig. 2A](#F2){ref-type="fig"}). Patients with cN0 disease who had a \~20% probability of micrometastases historically underwent superficial modified inguinal lymph node dissection for disease staging \[[@B17]\]. However, this procedure has complications in 10% to 36% of cases and is unnecessary in 80% of cases \[[@B18][@B19]\]. Kroon et al \[[@B20]\] reported that patients with pT2 and pT3 tumors who underwent groin dissection had a 3-year CSS rate of 84%, compared to 35% in those who did not undergo groin lymph node dissection. However, in our study, we did not analyze this parameter because many urologists did not conduct inguinal lymph node dissection routinely, and only 20 patients underwent inguinal lymph node dissection.

The treatment of primary invasive malignancy of the penis has traditionally involved radical amputation with a 2-cm margin for oncologic efficacy. Although these procedures have been found to provide excellent local control, amputation is associated with considerable voiding dysfunction, as well as psychological and sexual morbidity \[[@B21]\]. The surgical treatment of primary invasive penile cancer has changed over the past 10 years from radical amputation to penile-sparing surgery. The most common procedure for PSS is glansectomy, which was first described in 1996 \[[@B22]\]. The recurrence rates for glansectomy are less than 4%, with excellent oncologic outcomes \[[@B23][@B24][@B25][@B26][@B27]\]. Philippou et al \[[@B28]\] demonstrated that the rates of local recurrence and 5-year CSS after penile-sparing surgery were 8.9% and 91.7%, respectively, during a mean follow-up of 26 months. Bayles and Sethia \[[@B29]\] supported these excellent oncologic outcomes, reporting rates of local recurrence and cancer-specific mortality of 4.8% and 10.7%, respectively. In this study, the operation method (partial *vs*. total) was not significant for CSS.

This study had some limitations. First, it was an uncontrolled, retrospective study. All urologists who participated in this study did not use the same operative methods or decision-making strategies. Second, the number of patients in this study was small, and no central pathology review took place; therefore, further evaluation is necessary with a larger number of patients.

CONCLUSIONS
===========

Primary penile cancer is a rare malignancy. In our study, partial penectomy was the most common treatment. The overall oncologic outcomes were good, with a 5-year CSS rate of 84.0%. The AJCC stage and pathologic grade were found to affect survival in a multivariate analysis. These findings provide insights into the cultural, social, and health-related behaviors related to penile cancer in Korea.
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###### Patient characteristics
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  Variable                             Number (%)
  ------------------------------------ ------------
  Tumor type                           
   Squamous cell carcinoma             50 (96.2)
   Other                               2 (3.8)
  TNM Stage                            
   T                                   
    ≤1                                 23 (44.2)
    2                                  13 (25.0)
    3                                  14 (26.9)
    4                                  2 (3.8)
   N                                   
    0                                  35 (67.3)
    1                                  8 (15.4)
    2                                  5 (9.6)
    3                                  4 (7.7)
   M                                   
    0                                  48 (92.3)
    1                                  4 (7.7)
  AJCC stage                           
   I                                   21 (40.4)
   II                                  13 (25.0)
   IIIA                                5 (9.6)
   IIIB                                3 (5.8)
   IV                                  10 (19.2)
  Pathologic grade                     
   Well to moderately differentiated   43 (82.7)
   Poorly differentiated               9 (17.3)
  Mode of therapy                      
   Chemotherapy or radiation therapy   6 (11.5)
   Partial penectomy                   34 (65.4)
   Total penectomy                     12 (23.1)
  Lymph node dissection (n=46)         
   Not performed                       26 (56.5)
   Performed                           20 (43.5)

AJCC: American Joint Committee on Cancer.

###### Multivariable associations of clinicopathologic factors with survival
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  Variable                                Univariate analysis   Multivariate analysis                                    
  --------------------------------------- --------------------- ----------------------- --------------- ------- -------- ---------------
  Age                                     0.083                 1.055                   0.993\~1.121    \-      \-       \-
  Grade (≤G2 vs. ≥G3)                     0.019                 4.408                   1.270\~15.298   0.038   3.253    0.807\~13.116
  AJCC stage (≤IIIA vs. ≥IIIB)            0.000                 12.227                  3.128\~47.794   0.001   13.962   2.856\~68.250
  Mode of therapy (operation vs. other)   0.560                 0.631                   0.134\~2.937    \-      \-       \-
  Operative method (total vs. partial)    0.205                 0.315                   0.053\~1.880    \-      \-       \-

AJCC: American Joint Committee on Cancer, HR: hazard ratio, CI: confidence interval.
